Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.

ABSTRACT:

Background

In pediatric rheumatic diseases (PRD), adalimumab is dosed using fixed weight-based bands irrespective of methotrexate co-treatment, disease activity (DA) or other factors that might influence adalimumab pharmacokinetics (PK). In rheumatoid arthritis (RA) adalimumab exposure between 2-8 mg/L is associated with clinical response. PRD data on adalimumab is scarce. Therefore, this study aimed to analyze adalimumab PK and its variability in PRD treated with/without methotrexate.

Methods

A two-center prospective study in PRD patients aged 2-18 years treated with adalimumab and methotrexate (G_A-M) or adalimumab alone (G_A) for ≥ 12 weeks was performed. Adalimumab concentrations were collected 1-9 (maximum concentration; C_max), and 10-14 d

SUBMITTER: Welzel T 

PROVIDER: S-EPMC10763375 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature